Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

Background The combination of bevacizumab (B) and erlotinib (E) has shown promising clinical outcomes as the first-line treatment of advanced HCC patients. We aimed to evaluate the efficacy and safety of using combination of B + E in treating advanced HCC patients who had failed prior sorafenib trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Yau, Thomas, Wong, Hilda, Chan, Pierre, Yao, T. J., Pang, R., Cheung, T. T., Fan, S. T., Poon, Ronnie T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484314/
https://www.ncbi.nlm.nih.gov/pubmed/22402942
http://dx.doi.org/10.1007/s10637-012-9808-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484314/
https://www.ncbi.nlm.nih.gov/pubmed/22402942
http://dx.doi.org/10.1007/s10637-012-9808-8

Ejemplares similares